The National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix’s artificial intelligence (AI)-enabled software, Brainomix 360, to help clinical decision-making in strokes.
NICE advised that the software could be used within the NHS while further evidence was acquired to better determine its cost-effectiveness.
Responsible for over 100,000 cases in the UK every year, a stroke is a life-threatening medical condition that occurs when the blood supply to parts of the brain is cut off.
Previously called e-Stroke, Brainomix 360 was selected as one of two AI software’s from a dozen others after the health technology assessment agency found evidence of faster and better access to treatment after using the software.
The new guidance amplifies the stroke platform, which is now entering the US market, into an evidence generation framework, allowing stroke units across the UK to utilise the technology while further evidence is collected.
Evidence found by the Health Technology Assessment showed that patients admitted to the hospital with a suspected stroke had faster and improved access to treatment following the use of Brainomix 360.
Dr Michalis Papadakis, co-founder and chief executive officer, Brainomix, said: “This recommendation was driven by the emergence of… real-world evidence demonstrating the transformative impact of Brainomix 360 on stroke treatment, mechanical thrombectomy in particular.”
A report from Health Innovation Oxford and Thames Valley found that the average thrombectomy treatment rate in hospitals with Brainomix 360 was 55% higher than the national average.
“We are very pleased to receive this endorsement from NICE… [to help] clinicians make more confident decisions, leading to more patients getting access to life-saving treatments,” added Papadakis.
Already widely adopted across England, the technology has also been deployed in over 30 countries, including a national-level deployment in Wales and Hungary. More recently, Brainomix 360 has been launched in the US following a series of clearances by the US Food and Drug Administration.
